Oneness Biotech Co., Ltd. is committed to the our philosophy of “science, Integrity and transparency” and to the research and development of innovative drugs. We have an outstanding R&D team and great strength in innovation, work steadily in the field of new drugs, and continue to incorporate our patented technologies into the development of globally innovative drugs that are the best in class, the first in class, and capable of satisfying unmet medical needs. We aim to promote human health and improve people’s quality of life by providing safe, effective, and quality drugs.
Oneness Biotech Co., Ltd. has made significant progress in developing new drugs last year. FESPIXON® cream, our new drug for diabetic foot ulcers (DFU) passed the New Drug Application (NDA) of the Ministry of Health and Welfare and obtained the drug license. Nanchou Plant completed the PIC/S GMP and GDP certifications for the API plant and the finished pharmaceutical product plant. The details of Phase III MRCT clinical trials on FESPIXON® cream have been published in JAMA Network Open, an international medical journal. The result of clinical trials is much better than that of standard treatment. The R&D team continues to conduct academic and clinical research on FESPIXON® cream and works with major medical centers to evaluate the medication use on radiation ulcers, decubitus ulcers and varicose ulcers with an expectation to provide better treatment to patients. We also completed the Phase IIa clinical trial of FB825, a new drug for atopic dermatitis. According to the exploration results in this Phase IIa study, FB825 has met the anticipated treatment efficacy.
In response to the tremendous impact of COVID-19 globally, Oneness as a biotech company has diligently worked to develop SNS812, a RNA nucleic acid drug that targets and severs important gene sites of a coronavirus that do not mutate easily, to effectively inhibit 99.8% variants. The research result of SNS812 has been officially published in the world-leading journal, EMBO Molecular Medicine. It has been positively received by international virologists and RNA drug experts and they believe that RNA drugs like SNS812 may be the solution for variants and pave the way for new COVID-19 treatment. “New drug development” is our core business and our efforts are aligned with UN’s Sustainable Development Goal 3 to “ensure healthy lives and promote well-being for all at all ages”.
Oneness Biotech also abides by “Corporate Governance 3.0 - Sustainable Development Roadmap” established by Financial Supervisory Commission to safeguard shareholders’ rights, strengthen the Board’s structure and operation, increase information transparency, promote sustainable development and improve governance. In 2022, “the 8th Corporate Governance Evaluation Results” published by Taiwan Stock Exchange in April, Oneness Biotech ranked among the top 5% in the TPEx-listed companies. It is the highest honor in the evaluation. We also ranked in the top 10% of listed companies with a market capital of 10 billion TWD or more in the non-finance and non-electronics industry, recognizing Oneness’s excellent performance and efforts in corporate governance and sustainability. Oneness Biotech has committed to build a friendly workplace and promote gender equality and is the only Taiwan biotech company to be included in 2022 Bloomberg Gender-Equality Index in January.
Oneness Biotech has voluntarily issued the ESG Report in accordance with GRI standards for the third consecutive year and this year, the ESG Report is also third-party certified. In this report, we make our climate actions public in accordance with Task Force on Climate-related Financial Disclosures (TCFD), and disclose the ESG information based on the sustainability accounting standards (SASB) in accordance with the investment community’s required disclosures. To transform to a low-carbon emission operation, we have initiated a GHG inventory plan and completed the carbon footprint verification of FESPIXON® cream (ISO 14067). We will also establish the organization GHG emission list and obtain the ISO 14064 certification in 2022. Meanwhile, we increase energy use efficiency and promote measures to save energy and reduce carbon emission. Supply chain resilience is also one of our focal issues. We actively evaluate the sustainability risk of suppliers, revise suppliers’ management procedures and include ESG issues in the supplier evaluation criteria in order to build a “green” and “sustainable” supply chain.
The new drug business is established to solve human life and health problems with scientific innovation. Oneness Biotech shall hold on to the core business values of “integrity, innovation, and compassion” by forming integrity-based alliances, innovative expansion of blue ocean strategies, and giving back to society in a spirit of compassion. We will continue increasing our strength in research and development to develop world-class innovative drugs and help create a healthy life for humankind. We will incorporate sustainability strategies into business operation and development, carry out our corporate social responsibilities, and support a sustainable environment for future generations.
